FDA Approves Pregabalin Application ANDA219593 by Unichem
The FDA has approved the ANDA219593 application for Pregabalin submitted by Unichem.
Published: August 2, 2026
Updated: August 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Pain Management
Asset: Unichem
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Unichem
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Unichem's ANDA219593 for Pregabalin signifies a new competitor entering the pain management market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications for existing Pregabalin products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent pricing strategies from Unichem.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.